Literature DB >> 10549711

Production and chemical processing of low molecular weight heparins.

R J Linhardt1, N S Gunay.   

Abstract

Heparin is an animal tissue extract that is widely used as an anticoagulant drug. A number of low molecular weight heparins (LMWHs), introduced in the past decade, are beginning to displace pharmaceutical (or compendial) grade heparins as clinical antithrombotic agents. This article describes the chemical properties of the glycosaminoglycan (GAG) heparin and how it is prepared and processed into pharmaceutical grade heparin. There are several commercially produced LMWHs that are prepared through the controlled depolymerization of pharmaceutical grade heparin. The chemistry of the commercial processes used for manufacturing LMWHs is discussed. Structural differences are found in the LMWHs prepared using different commercial processes. Careful control of process variables has generally resulted in the reproducible preparation of LMWHs that are structurally uniform and of high quality. The specifications, however, remain different for each LMWH. Thus, LMWHs are a group of similar but different drug agents. As the structural properties of LMWHs vary significantly, the bio-equivalence or inequivalence of these agents must ultimately be established by the pharmacologists and the clinicians.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10549711

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  86 in total

1.  Heparin sequencing brings structure to the function of complex oligosaccharides.

Authors:  M A Nugent
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

2.  Heparinase 1 selectivity for the 3,6-di-O-sulfo-2-deoxy-2-sulfamido-alpha-D-glucopyranose (1,4) 2-O-sulfo-alpha-L-idopyranosyluronic acid (GlcNS3S6S-IdoA2S) linkages.

Authors:  Zhongping Xiao; Wenjing Zhao; Bo Yang; Zhenqing Zhang; Huashi Guan; Robert J Linhardt
Journal:  Glycobiology       Date:  2010-08-20       Impact factor: 4.313

Review 3.  Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?

Authors:  Ludovic Drouet
Journal:  Target Oncol       Date:  2012-01-25       Impact factor: 4.493

4.  Linear polyalkylamines as fingerprinting agents in capillary electrophoresis of low-molecular-weight heparins and glycosaminoglycans.

Authors:  J Timothy King; Umesh R Desai
Journal:  Electrophoresis       Date:  2011-10-17       Impact factor: 3.535

Review 5.  Trousseau's syndrome: multiple definitions and multiple mechanisms.

Authors:  Ajit Varki
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113

6.  Investigation of Luminescence Characteristics of Osmium(II) Complexes in the Presence of Heparin Polyanions.

Authors:  Yixi Xie; Yu Lei; Shalini Shah; Hao Wu; Jian Wu; Elise Megehee; Enju Wang
Journal:  Int J Anal Chem       Date:  2013-07-16       Impact factor: 1.885

7.  Interaction of Zika Virus Envelope Protein with Glycosaminoglycans.

Authors:  So Young Kim; Jing Zhao; Xinyue Liu; Keith Fraser; Lei Lin; Xing Zhang; Fuming Zhang; Jonathan S Dordick; Robert J Linhardt
Journal:  Biochemistry       Date:  2017-02-13       Impact factor: 3.162

8.  Combinatorial one-pot chemoenzymatic synthesis of heparin.

Authors:  Ujjwal Bhaskar; Guoyun Li; Li Fu; Akihiro Onishi; Mathew Suflita; Jonathan S Dordick; Robert J Linhardt
Journal:  Carbohydr Polym       Date:  2014-11-07       Impact factor: 9.381

9.  Bioengineering murine mastocytoma cells to produce anticoagulant heparin.

Authors:  Leyla Gasimli; Charles A Glass; Payel Datta; Bo Yang; Guoyun Li; Trent R Gemmill; Jong Youn Baik; Susan T Sharfstein; Jeffrey D Esko; Robert J Linhardt
Journal:  Glycobiology       Date:  2013-12-09       Impact factor: 4.313

Review 10.  Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review.

Authors:  Gregory Egan; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2015 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.